{
  "id": 16263264,
  "title": "Vertex at ASN Kidney Week 2026: renal push gathers pace",
  "url": "https://urgent.news/2026/10/24/vertex-at-asn-kidney-week-2026-renal-push-gathers-pace",
  "topic": "world",
  "section": "World",
  "published": "2026-10-24T01:17:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/vertex-at-asn-kidney-week-2026-renal-push-gathers-pace-93CH-4970541"
  },
  "original_language": "en",
  "account": null,
  "summary": "Vertex Pharmaceuticals showcased its expanding kidney pipeline at ASN Kidney Week 2026, with new data on IgA nephropathy and APOL1-mediated kidney disease. The company highlighted strong clinical results in povetacicept, a B-cell modulator, which showed a 52% reduction in proteinuria at 36 weeks in IgA nephropathy, with a favorable safety profile. Inaxaplin continued to demonstrate meaningful proteinuria reductions in APOL1-mediated kidney disease, supporting its Phase III program. Vertex executives emphasized the company's transition into a renal-focused entity, aiming for a kidney franchise worth $10 billion across four diseases. The main near-term catalysts for povetacicept are the November 30 FDA decision date and early 2027 interim data from the AMPLITUDE study. With a market capitalization of $135.6 billion, Vertex remains a prominent biotechnology player, diversifying from its cystic fibrosis franchise.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}